Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 68, Issue 3, Pages 341-352Publisher
SPRINGER
DOI: 10.1007/s00262-019-02310-2
Keywords
Biomarker; Immune checkpoint inhibitors; Immunotherapy; Long-term survival; Non-small cell lung cancer; PD-L1
Categories
Funding
- Bristol-Myers Squibb
- Department of Health of the Generalitat de Catalunya [SLT006/17/00127]
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)-programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Furthermore, increasing evidence shows that excessive activation of the immune response elicited by ICIs, leading to immune-related toxicities, might be associated with an improved response to immunotherapy. There are still many unanswered questions about the proper use of these agents to maximize their efficacy, which may be improved through combination with radiation, chemotherapy, targeted therapies, or other immune mediators, including dual checkpoint blockade. To search for clues for addressing these challenges, this review focused on the characteristics and clinical features of long-term NSCLC survivors and the potential biomarkers of response to ICIs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available